Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD34+ HSC Mobilization and Apheresis in RUNX1-FPD
NCT06414889Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2024
- Primary completion
- Jun 2027
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of filgrastim and plerixafor in familial platelet disorder with associated myeloid malignancy (FPD/AML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started May 2024; status: recruiting.
02
Drugs
filgrastimplerixafor
03
Conditions
familial platelet disorder with associated myeloid malignancy (FPD/AML)
Beyond the preview
Go deeper on NCT06414889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414889.